Profiles

Keywords
Last Name
Institution

Donald Jensen

Concepts (227)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Antiviral Agents
31
2019
138
10.530
Why?
Hepatitis C, Chronic
28
2019
82
9.430
Why?
Hepacivirus
28
2019
71
7.470
Why?
Ribavirin
19
2016
32
4.810
Why?
Interferon-alpha
20
2016
82
4.780
Why?
Hepatitis C
12
2016
65
4.370
Why?
Polyethylene Glycols
17
2016
55
4.330
Why?
Drug Therapy, Combination
17
2016
264
1.940
Why?
Protease Inhibitors
4
2016
21
1.760
Why?
Sulfonamides
6
2019
63
1.570
Why?
Recombinant Proteins
20
2016
306
1.510
Why?
Gastroenterology
4
2016
16
1.220
Why?
Oligopeptides
2
2016
34
1.210
Why?
Interferons
3
2015
17
1.180
Why?
Liver Transplantation
4
2012
107
1.140
Why?
RNA, Viral
13
2016
169
1.100
Why?
Proline
2
2013
13
1.020
Why?
Genotype
11
2016
435
0.960
Why?
Humans
50
2019
29841
0.920
Why?
Quinoxalines
1
2019
10
0.850
Why?
Benzimidazoles
1
2019
12
0.840
Why?
Drug Design
1
2019
37
0.820
Why?
Viral Nonstructural Proteins
2
2016
9
0.790
Why?
Liver
5
2016
213
0.760
Why?
Treatment Outcome
15
2016
3788
0.720
Why?
Viral Load
7
2016
208
0.690
Why?
Drug Approval
2
2016
33
0.690
Why?
Drugs, Generic
1
2016
4
0.690
Why?
Thiazoles
1
2016
39
0.670
Why?
Benzothiadiazines
1
2015
1
0.660
Why?
Liver Diseases
2
2016
39
0.660
Why?
Quinolones
1
2015
23
0.660
Why?
Serine Proteinase Inhibitors
2
2012
3
0.630
Why?
Hepatitis B, Chronic
1
2014
8
0.600
Why?
Coinfection
1
2014
33
0.590
Why?
Editorial Policies
1
2014
6
0.580
Why?
Journal Impact Factor
1
2014
13
0.580
Why?
Kidney Transplantation
2
2008
143
0.560
Why?
Periodicals as Topic
1
2014
40
0.540
Why?
Time Factors
7
2016
1894
0.540
Why?
Drug Monitoring
1
2013
28
0.540
Why?
Monitoring, Immunologic
1
2012
2
0.520
Why?
Middle Aged
21
2016
11053
0.520
Why?
Immunosuppression
1
2012
38
0.510
Why?
Interleukins
1
2012
40
0.500
Why?
Graft Rejection
1
2012
85
0.490
Why?
Polymorphism, Genetic
1
2012
95
0.480
Why?
Anemia
2
2011
90
0.470
Why?
Adult
19
2016
9591
0.460
Why?
Male
23
2016
17153
0.460
Why?
CD4-Positive T-Lymphocytes
1
2012
219
0.450
Why?
Drug Administration Schedule
6
2016
265
0.440
Why?
Hepatitis B
1
2010
20
0.430
Why?
Female
22
2016
17657
0.420
Why?
Genetic Predisposition to Disease
1
2012
469
0.400
Why?
Transaminases
1
2008
7
0.400
Why?
Randomized Controlled Trials as Topic
5
2016
357
0.390
Why?
Bile Ducts, Intrahepatic
1
2008
7
0.380
Why?
Cholestasis, Intrahepatic
1
2008
6
0.380
Why?
DNA-Directed RNA Polymerases
1
2008
3
0.380
Why?
Heart Transplantation
1
2008
52
0.380
Why?
Retreatment
4
2014
18
0.380
Why?
United States
6
2016
2402
0.360
Why?
Enzyme Inhibitors
1
2008
160
0.360
Why?
HIV Infections
1
2014
902
0.350
Why?
Clinical Trials as Topic
4
2012
382
0.350
Why?
Interferon Type I
2
2003
20
0.340
Why?
Remission Induction
3
2015
125
0.330
Why?
Treatment Failure
4
2009
186
0.320
Why?
Lactams
2
2015
7
0.320
Why?
Hospital Departments
1
2005
9
0.320
Why?
Liver Cirrhosis
2
2016
61
0.320
Why?
Logistic Models
3
2016
478
0.310
Why?
Ritonavir
2
2014
18
0.300
Why?
Nucleotidases
1
2004
1
0.290
Why?
gamma-Glutamyltransferase
1
2004
3
0.290
Why?
Hospital Costs
1
2005
74
0.290
Why?
Cholestasis
1
2004
9
0.290
Why?
Alkaline Phosphatase
1
2004
16
0.290
Why?
Academic Medical Centers
1
2005
156
0.290
Why?
Hepatitis C Antibodies
1
2003
5
0.280
Why?
Cyclosporine
1
2003
19
0.270
Why?
Internship and Residency
2
2016
182
0.260
Why?
Dose-Response Relationship, Drug
6
2014
524
0.260
Why?
United States Food and Drug Administration
2
2016
77
0.260
Why?
Follow-Up Studies
5
2014
2017
0.230
Why?
Kidney Failure, Chronic
1
2002
168
0.220
Why?
Molecular Conformation
1
2019
17
0.210
Why?
Microbial Sensitivity Tests
1
2019
111
0.210
Why?
Predictive Value of Tests
2
2013
617
0.200
Why?
Retrospective Studies
4
2014
3303
0.180
Why?
Double-Blind Method
4
2014
541
0.170
Why?
Counterfeit Drugs
1
2016
2
0.170
Why?
Drug and Narcotic Control
1
2016
8
0.170
Why?
Commerce
1
2016
11
0.170
Why?
Canada
1
2016
55
0.170
Why?
Fraud
1
2016
10
0.170
Why?
Quality Control
1
2016
48
0.170
Why?
Safety
1
2016
57
0.170
Why?
Clinical Trials, Phase III as Topic
1
2016
29
0.170
Why?
Retinoids
1
2016
8
0.170
Why?
Carotenoids
1
2016
10
0.170
Why?
Isoquinolines
1
2016
17
0.170
Why?
New Zealand
1
2015
14
0.170
Why?
Intracellular Signaling Peptides and Proteins
1
2016
55
0.170
Why?
Australia
1
2015
43
0.160
Why?
Actins
1
2016
60
0.160
Why?
Europe
1
2015
83
0.160
Why?
Deoxycytidine
1
2015
49
0.160
Why?
Carrier Proteins
1
2016
130
0.160
Why?
Uridine Monophosphate
1
2015
2
0.160
Why?
Imidazoles
1
2016
72
0.160
Why?
Heterocyclic Compounds, 3-Ring
1
2015
15
0.150
Why?
Odds Ratio
1
2016
328
0.150
Why?
Uracil
1
2014
5
0.150
Why?
Phenotype
1
2015
360
0.150
Why?
Anilides
1
2014
11
0.150
Why?
Macrocyclic Compounds
1
2014
6
0.150
Why?
Carbamates
1
2014
9
0.150
Why?
Education, Medical, Graduate
1
2015
82
0.150
Why?
Biopsy
4
2016
278
0.140
Why?
Cost-Benefit Analysis
1
2014
144
0.140
Why?
Health Care Costs
1
2014
79
0.140
Why?
Terminology as Topic
1
2012
52
0.130
Why?
African Continental Ancestry Group
2
2011
172
0.130
Why?
Nucleosides
1
2012
3
0.130
Why?
Immunoassay
1
2012
42
0.130
Why?
Immunity, Cellular
1
2012
70
0.130
Why?
Drug Delivery Systems
1
2012
41
0.120
Why?
Genetic Testing
1
2012
75
0.120
Why?
Immunosuppressive Agents
1
2012
167
0.110
Why?
Hepatitis B virus
1
2010
7
0.110
Why?
Molecular Epidemiology
1
2010
26
0.110
Why?
Patient Selection
1
2012
249
0.110
Why?
Global Health
1
2010
57
0.110
Why?
Risk Factors
3
2012
2549
0.100
Why?
Fatty Liver
1
2009
40
0.100
Why?
Prognosis
1
2012
1025
0.100
Why?
Graft Survival
1
2008
111
0.090
Why?
Aged
5
2014
9833
0.090
Why?
Hemoglobins
1
2008
76
0.090
Why?
Secondary Prevention
1
2007
62
0.090
Why?
Ethnic Groups
1
2009
176
0.090
Why?
Biomedical Research
1
2008
85
0.090
Why?
Evidence-Based Medicine
1
2008
233
0.090
Why?
RNA
1
2006
32
0.080
Why?
Pilot Projects
2
2008
425
0.080
Why?
Internal Medicine
2
2016
30
0.080
Why?
Sample Size
1
2005
27
0.080
Why?
Mutation
1
2008
445
0.080
Why?
Health Expenditures
1
2005
17
0.080
Why?
Practice Guidelines as Topic
1
2008
382
0.080
Why?
Hepatitis
1
2004
9
0.080
Why?
Curriculum
2
2016
153
0.070
Why?
Postoperative Complications
1
2012
1059
0.070
Why?
International Cooperation
2
2016
37
0.070
Why?
Autoantibodies
1
2004
114
0.070
Why?
Viral Vaccines
1
2003
2
0.070
Why?
Cross Reactions
1
2003
27
0.070
Why?
Viral Envelope Proteins
1
2003
26
0.070
Why?
Viral Proteins
1
2003
34
0.070
Why?
Sampling Studies
1
2003
31
0.070
Why?
Research Design
1
2005
227
0.070
Why?
Living Donors
1
2003
16
0.070
Why?
Injections, Subcutaneous
1
2003
44
0.070
Why?
Drug Resistance
1
2003
67
0.070
Why?
Databases, Factual
1
2005
357
0.070
Why?
Probability
1
2003
107
0.070
Why?
Immunoglobulin G
1
2003
136
0.070
Why?
Prospective Studies
1
2008
1809
0.070
Why?
Alanine Transaminase
2
2016
24
0.070
Why?
Statistics, Nonparametric
1
2003
162
0.070
Why?
Sialoglycoproteins
1
2002
9
0.060
Why?
General Surgery
1
2003
60
0.060
Why?
Attitude of Health Personnel
1
2003
177
0.060
Why?
Case-Control Studies
1
2002
684
0.050
Why?
Cohort Studies
1
2005
1911
0.050
Why?
Viremia
2
2012
36
0.050
Why?
Career Choice
1
2016
32
0.040
Why?
Retinol-Binding Proteins, Plasma
1
2016
1
0.040
Why?
Isoprostanes
1
2016
2
0.040
Why?
Lipid Peroxidation
1
2016
10
0.040
Why?
beta Carotene
1
2016
14
0.040
Why?
Vitamin A
1
2016
7
0.040
Why?
Chromatography, High Pressure Liquid
1
2016
44
0.040
Why?
Diterpenes
1
2016
10
0.040
Why?
Tandem Mass Spectrometry
1
2016
22
0.040
Why?
Hepatic Stellate Cells
1
2016
10
0.040
Why?
Enzyme-Linked Immunosorbent Assay
1
2016
149
0.040
Why?
Adolescent
2
2014
2591
0.040
Why?
Carcinoma, Hepatocellular
1
2016
44
0.040
Why?
Young Adult
2
2014
2198
0.040
Why?
Risk
1
2016
231
0.040
Why?
Hospitals, University
1
2015
45
0.040
Why?
Needs Assessment
1
2015
49
0.040
Why?
Oxidative Stress
1
2016
132
0.040
Why?
Cytochrome P-450 CYP3A Inhibitors
1
2014
3
0.040
Why?
Drug Carriers
1
2014
9
0.040
Why?
Liver Neoplasms
1
2016
124
0.040
Why?
Immunohistochemistry
1
2016
497
0.040
Why?
Drug Combinations
1
2014
86
0.040
Why?
Chronic Disease
1
2016
530
0.040
Why?
Clinical Competence
1
2016
268
0.030
Why?
Animals
1
2003
5125
0.030
Why?
Limit of Detection
1
2012
4
0.030
Why?
Cross-Sectional Studies
1
2016
915
0.030
Why?
Disease Progression
1
2016
843
0.030
Why?
Endpoint Determination
1
2012
31
0.030
Why?
Sex Factors
1
2012
524
0.030
Why?
Severity of Illness Index
1
2016
1220
0.030
Why?
Age Factors
1
2012
912
0.030
Why?
Aspartate Aminotransferases
1
2009
19
0.030
Why?
Triglycerides
1
2009
48
0.030
Why?
Asian Continental Ancestry Group
1
2009
51
0.020
Why?
Cholesterol
1
2009
65
0.020
Why?
Continental Population Groups
1
2009
113
0.020
Why?
Hispanic Americans
1
2009
218
0.020
Why?
European Continental Ancestry Group
1
2009
593
0.020
Why?
Public Opinion
1
2003
5
0.020
Why?
Illinois
1
2004
265
0.020
Why?
Ethics, Medical
1
2003
17
0.020
Why?
Data Collection
1
2003
118
0.020
Why?
Prevalence
1
2004
533
0.020
Why?
Interleukin 1 Receptor Antagonist Protein
1
2002
15
0.020
Why?
Drug Resistance, Viral
1
2002
43
0.020
Why?
Health Services Accessibility
1
2003
106
0.020
Why?
Recurrence
1
2003
383
0.020
Why?
Jensen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description